Status:
COMPLETED
Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne
Lead Sponsor:
BioWest Therapeutics Inc
Conditions:
Acne Vulgaris
Acne
Eligibility:
All Genders
12+ years
Phase:
PHASE2
Brief Summary
This is a Phase II, randomized, vehicle-controlled, double-blind, multi center study to evaluate the efficacy and safety of topically applied MBI 226 1.25% and 2.5% Acne Solutions as anti-acne prepara...
Eligibility Criteria
Inclusion
- Males and females 12 years and older
- Presence of inflammatory and non-inflammatory lesions
Exclusion
- Acne conglobata, acne fulminans, or secondary acne (chloracne, drug-induced acne, etc.)
- Active facial cysts or any nodulocystic lesions
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
End Date :
September 1 2003
Estimated Enrollment :
255 Patients enrolled
Trial Details
Trial ID
NCT00211497
Start Date
January 1 2003
End Date
September 1 2003
Last Update
September 21 2005
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.